Ireland
--:--IST
Enrolling by invitation Phase 1

Preoperative Nebulized Dexmedetomidine Versus Nebulized Magnesium Sulphate in Reducing Emergence Agitation in FESS

NCT07677917 · tracked via the Priya Life Science Egypt tracker
Phase
Phase 1
Started
2026-01-22
Last updated
2026-07-22

Condition(s) studied

Screening

Investigational drug(s) / intervention(s)

Dexmedetomidine →Magnesium sulfate →

Dexmedetomidine: Patients in Group D will be nebulized with 1 μg/kg nebulized dexmedetomidine completed to 3 ml using normal saline 30 min before operation.The solution for nebulization will be administered by an anesthesiologist.

Magnesium sulfate: Patients in Group M will be nebulized with 250 mg nebulized magnesium sulphate completed to 3 ml using normal saline 30 min before operation . The solution for nebulization will be administered by an anesthesiologist.

Study summary

Emergence agitation after sinus surgery is a common postoperative complication characterized by confusion, disorientation, and potentially violent behavior as a patient wakes from general anesthesia.This study compare the effect of nebulized dexmedetomidine versus nebulized magnesium sulphate in reducing emergence agitation in adult undergoing functional endoscopic sinus surgery.

This study aims to compare preoperative nebulized dexmedetomidine and nebulized magnesium sulphate in reducing emergence agitation in adult undergoing functional endoscopic sinus surgery.

Eligibility

Sex
ALL
Min age
21 Years
Max age
50 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Adult patients between 21 and 50 years of age undergoing elective functional endoscopic sinus surgery. 2. American Society of Anesthesiologists physical status classification (ASA) I and II. Exclusion Criteria: 1. Patient's refusal. 2. Complicated sinus surgery. 3. History of allergy to any of the study drugs. 4. Baseline HR≤60 beat/min. 5. Baseline mean arterial pressure (MAP)≤70 mmHg. 6. Psychiatric illness. 7. Cerebrovascular insufficiency. 8. Pregnancy.

Primary outcome measure(s)

  • The primary endpoint will Visual Analogue Scale (VAS)score after anesthesia — 30 minutes after operation in PACU
    Pain will be assessed by VAS Score where 0 is no pain and 10 is the worst pain possible

Trial sites (1)

FacilityCityRegionStatus
Ain Shams University Hospitals Cairo Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07677917 on ClinicalTrials.gov ↗ ← All trials in Egypt